T1	intervention 128 138	exemestane
T2	control 142 159	megestrol acetate
T3	eligibility 342 380	patients with metastatic breast cancer
T4	total-participants 415 418	769
T5	total-participants 803 805	53
T6	intervention-participants 816 818	24
T7	control-participants 841 843	29
T10	outcome 1005 1030	suppression of E2 and E1S
T15	outcome 1162 1177	IGF-1 increased
T16	outcome 1250 1265	Estrogen levels
T8	outcome 900 904	ICTP
T9	outcome 909 912	BAP
